Compare Panacea Biotech with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GSK PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GSK PHARMA PANACEA BIOTECH/
GSK PHARMA
 
P/E (TTM) x 10.6 32.4 32.5% View Chart
P/BV x 2.2 12.9 17.3% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 PANACEA BIOTECH   GSK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
GSK PHARMA
Mar-19
PANACEA BIOTECH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3543,595 9.8%   
Low Rs1381,253 11.0%   
Sales per share (Unadj.) Rs74.6184.7 40.4%  
Earnings per share (Unadj.) Rs6.726.3 25.4%  
Cash flow per share (Unadj.) Rs15.529.2 53.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs57.2126.3 45.3%  
Shares outstanding (eoy) m61.25169.40 36.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.313.1 25.1%   
Avg P/E ratio x36.892.2 39.9%  
P/CF ratio (eoy) x15.983.1 19.1%  
Price / Book Value ratio x4.319.2 22.4%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m15,061410,626 3.7%   
No. of employees `0002.35.0 46.7%   
Total wages/salary Rs m1,4715,372 27.4%   
Avg. sales/employee Rs Th1,973.66,306.7 31.3%   
Avg. wages/employee Rs Th635.61,083.1 58.7%   
Avg. net profit/employee Rs Th176.8898.0 19.7%   
INCOME DATA
Net Sales Rs m4,56731,281 14.6%  
Other income Rs m451,023 4.4%   
Total revenues Rs m4,61232,304 14.3%   
Gross profit Rs m2,0306,009 33.8%  
Depreciation Rs m540486 111.1%   
Interest Rs m1,0486 17,471.7%   
Profit before tax Rs m4866,540 7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m772,373 3.2%   
Profit after tax Rs m4094,454 9.2%  
Gross profit margin %44.419.2 231.4%  
Effective tax rate %15.936.3 43.7%   
Net profit margin %9.014.2 62.9%  
BALANCE SHEET DATA
Current assets Rs m2,41520,061 12.0%   
Current liabilities Rs m9,07714,543 62.4%   
Net working cap to sales %-145.917.6 -827.0%  
Current ratio x0.31.4 19.3%  
Inventory Days Days6557 114.6%  
Debtors Days Days7114 504.4%  
Net fixed assets Rs m8,33314,343 58.1%   
Share capital Rs m611,694 3.6%   
"Free" reserves Rs m3,44319,704 17.5%   
Net worth Rs m3,50421,398 16.4%   
Long term debt Rs m4612 23,060.0%   
Total assets Rs m13,75539,113 35.2%  
Interest coverage x1.51,091.0 0.1%   
Debt to equity ratio x0.10 140,823.2%  
Sales to assets ratio x0.30.8 41.5%   
Return on assets %10.611.4 92.9%  
Return on equity %11.720.8 56.1%  
Return on capital %38.731.9 121.2%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,203534 225.3%   
Fx outflow Rs m4677,091 6.6%   
Net fx Rs m736-6,557 -11.2%   
CASH FLOW
From Operations Rs m1,0493,994 26.3%  
From Investments Rs m-54-1,433 3.7%  
From Financial Activity Rs m-1,011-3,584 28.2%  
Net Cashflow Rs m-20-1,023 1.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.6 10.2 5.9%  
FIIs % 1.3 23.8 5.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 15.4 153.2%  
Shareholders   10,259 102,036 10.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling; Sensex Down 235 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 22, 2019 03:29 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS